Improvement of Pretibial Myxedema Following Administration of Teprotumumab

Abigail Washington, Hannah Nam, Michelle Pitch, Bryan Anderson, Jennifer Stokes, Matthew F. Helm

Research output: Contribution to journalArticlepeer-review


Pretibial myxedema (PTM) is a rare complication of Graves’ disease. It is characterized by non-pitting edema with hyperpigmented hyperkeratotic papules and plaques on bilateral lower legs. Effective treatments for patients with PTM are lacking.The etiology of PTM is unknown; however, it may be similar to the mechanism of thyroid-associated ophthalmopathy (TAO). Activated fibroblasts produce inflammatory cytokines and synthesize excessive glycosaminoglycans (GAG) that accumulate in the dermis and subcutaneous tissue. A recent, novel pathway implicates IGF-1 receptor as a mediator in this process. We present two patients with refractory PTM that improved following treatment with teprotumumab, an IGF-1 receptor inhibitor approved for use inTAO.

Original languageEnglish (US)
Pages (from-to)1252-1254
Number of pages3
JournalJournal of Drugs in Dermatology
Issue number11
StatePublished - Nov 2022

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Improvement of Pretibial Myxedema Following Administration of Teprotumumab'. Together they form a unique fingerprint.

Cite this